SP
Symbiotec Pharmalab Limited IPO
Pharmaceuticals & Biotechnology · APIs · Corticosteroids · Nutraceuticals
📋 Mainline IPO
Fresh + OFS
NSE, BSE
₹988
Upper Price
₹1,757.00 Cr
Issue Size
Sep 1, 2026
Listing Date
₹6,094.00 Cr
Market Cap (Pre)
📅 IPO Timetable
All dates tentative🟢
IPO Opens
Monday, 24 August 2026
Bidding starts — apply before close
🔒
IPO Closes
Thursday, 27 August 2026
Last day to bid — closes at 5:00 PM IST
📊
Basis of Allotment
Friday, 28 August 2026
Allotment finalised by registrar
🔄
Refund & Share Credit
Monday, 31 August 2026
Unallotted funds returned; shares credited to demat
🏷️
Tuesday, 1 September 2026
Trading begins from 10:00 AM IST
📋 IPO Details
IPO Open Date24 August 2026 (Mon)
IPO Close Date27 August 2026 (Thu)
Listing Date1 September 2026 (Tue)
Face Value₹2 per share
Price Band₹938 to ₹988
Issue Price (Upper Band)₹988 per share
Issue TypeBook Build — Fresh + OFS
Lot Size15 shares
Total Issue Size1,77,86,442 shares (₹1,757.00 Cr)
Fresh Issue15,21,261 shares (₹150.00 Cr)
Offer for Sale (OFS)1,62,65,181 shares (₹1,607.00 Cr)
Pre-Issue Shares6,16,81,496
Post-Issue Shares6,32,02,757
Promoter Holding (Pre)34.47%
Market Cap (Pre-IPO)₹6,094.00 Cr
Listing ExchangeNSE, BSE
Lead ManagerJM Financial, Avendus, Motilal Oswal, Nomura
RegistrarMUFG Intime India Pvt.Ltd.
💰 Lot Size & Minimum Investment
At upper price ₹988| Investor Type | Lots | Shares | Amount |
|---|---|---|---|
| Retail — Minimum | 1 | 15 | ₹14,820 |
| Retail — Maximum | 13 | 195 | ₹1,92,660 |
| S-HNI (sNII) — Min | 14 | 210 | ₹2,07,480 |
| S-HNI (sNII) — Max | 67 | 1,005 | ₹9,92,940 |
| B-HNI (bNII) — Min | 68 | 1,020 | ₹10,07,760 |
⚠️ Note: Investors can bid for a minimum of 15 shares and in multiples thereof. Retail individual investors can apply up to ₹2,00,000. Employee discount of ₹90.00 per share is applicable.
👥 Investor Reservation
Allocated portion of Net OfferNot more than 50%
QIB Portion
Not less than 35%
Retail Portion
Not less than 15%
NII Portion
📊 Subscription Status
Loading…
📈 Company Financials
Restated Consolidated · ₹ Crore| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| PAT | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| Net Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves & Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Income Growth
FY 2023–24₹723.33 Cr
FY 2024–25₹755.98 Cr
FY 2025–26₹872.26 Cr
🎯 Key Performance Indicators
11.19%
ROE
FY 2025–26
11.56%
ROCE
FY 2025–26
12.60%
PAT Margin
FY 2025–26
26.59%
EBITDA Margin
FY 2025–26
9.48%
RoNW
FY 2025–26
5.35x
Price/Book
FY 2025–26
184.69
NAV
FY 2025–26
584.67 MT
Capacity
API Synthesis
⚖️ Valuation & EPS
Pre-IPO EPS
₹17.82
FY26 earnings + pre-issue shares
P/E: 55.44xPost-IPO EPS
₹17.39
FY26 earnings + post-issue shares
P/E: 56.81xPrice to Book Value
5.35x
At upper price band ₹988
Market Cap (Pre-IPO)
₹6,094.00 Cr
At issue price ₹988
ℹ️
Pre-IPO EPS (₹17.82) based on pre-issue shares (6,16,81,496) and FY26 earnings. Post-IPO EPS (₹17.39) accounts for the dilution resulting from the issuance of 15,21,261 fresh equity shares extending the total post-issue equity to 6,32,02,757 shares. Post-IPO Market Cap expands to ₹6,244.43 Cr.
🎯 Objects of the Issue
Net proceeds utilisation1
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
₹112.50 Cr
2
General corporate purposes
Balance
Total Fresh Issue Goal
₹150.00 Cr
🏢 About Symbiotec Pharmalab Ltd.
Est. 2002 · Indore, Madhya Pradesh · Pharmaceuticals & APIsSymbiotec Pharmalab Ltd., incorporated in 2002, is a leading research-driven pharmaceutical and biotechnology enterprise engaging vigorously in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), nutritional components, and specialty products. Transitioning aggressively from a lab-scale operation in 1995 to a massive industrial-scale, backward-integrated manufacturing platform, Symbiotec now commands global leadership specifically in corticosteroid and steroidal hormone APIs.
The company supplies high-quality ingredients serving vast domestic and international networks across both regulated and emerging regions. Its deep operational footprint is secured by two advanced API manufacturing setups supporting 584.67 MT in chemical synthesis and 300 KL in fermentation capacity. Demonstrating stringent quality compliance, Symbiotec possesses elite approvals from the US FDA, EU-GMP, and the Ministry of Food and Drug Safety, Korea, powering sustainable expansion within the global nutraceutical and wellness verticals.
Brand Ecosystem
💊
API Manufacturing
Corticosteroid and steroidal hormone APIs backed by top global approvals
🌿
Specialty Products
Nutritional ingredients and advanced research-driven health solutions
🌍
Global Reach
Exporting extensively to heavily regulated and emerging markets across multiple regions
🏭
Industrial Scale
Commanding chemical synthesis capacity of 584.67 MT and fermentation of 300 KL
Competitive Strengths
🏆Undisputed global leadership footprint in critical corticosteroid and steroidal hormone APIs
🤝Deep-rooted, long-standing collaborative relationships with leading domestic and international pharma entities
⚙️Fully invested, multi-scale, vertically integrated manufacturing grids maintaining strict sustainable practices
💡Continuous heavy investment in advanced R&D yielding strong intellectual property-driven technological capabilities
Company Promoters
AS
Anil Satwani & Sushil Satwani
Promoters, Symbiotec Pharmalab Ltd.
KS
Kashish Satwani & Satwani Holdings LLP
Promoters, Symbiotec Pharmalab Ltd.
📅 Key Dates
IPO Opens24 Aug 2026
IPO Closes27 Aug 2026
Allotment28 Aug 2026
Refund & Share Credit31 Aug 2026
Listing Day01 Sep 2026
💡 Quick Summary
Price Band₹938 – ₹988
Upper Price₹988 / share
Lot Size15 shares
Min. Investment (Retail)₹14,820
Issue Size₹1,757.00 Cr
ListingBSE, NSE
🏦 Registrar & Lead Manager
Lead Manager
JM Financial, Avendus, Motilal Oswal, Nomura
📍 Registered Address
Symbiotec Pharmalab Ltd.
385/2, Pigdamber, Rau,
Mhow, Indore,
Madhya Pradesh — 453331
📞 +91 731 667 6405
[email protected]
385/2, Pigdamber, Rau,
Mhow, Indore,
Madhya Pradesh — 453331
📞 +91 731 667 6405
[email protected]
🛡️ Regulatory Note: Mainline IPO investments are subject to SEBI regulations. Always read the Prospectus/RHP before applying. Consult a SEBI-registered advisor before investing.
⚠️
Disclaimer: This page presents publicly available information from the Symbiotec Pharmalab IPO RHP for informational purposes only. It does not constitute investment advice. IPO investments are subject to market risk. Please read all offer documents and consult a SEBI-registered advisor before investing.
📊
Track Symbiotec Pharmalab IPO 2026: ₹1,757 Crore Issue, Price Band, GMP & Key Details GMP
Check real-time grey market premium, daily GMP history & estimated listing price.
Check GMP →